Omega Fund Management’s Arcutis Biotherapeutics ARQT Stock Holding History

Omega Fund Management’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-623,836	Closed	-$13.3M	–	20
2022 Q2	$13.3M	Hold	623,836	–	–	4.24%	8
2022 Q1	$12M	Hold	623,836	–	–	2.46%	11
2021 Q4	$12.9M	Hold	623,836	–	–	1.83%	11
2021 Q3	$14.9M	Hold	623,836	–	–	1.67%	12
2021 Q2	$17M	Hold	623,836	–	–	1.93%	10
2021 Q1	$18M	Sell	623,836 -16,363	-3%	-$511K	1.71%	12
2020 Q4	$18M	Sell	640,199 -18,709	-3%	-$458K	2.7%	9
2020 Q3	$19.3M	Sell	658,908 -185,772	-22%	-$4.96M	5.22%	5
2020 Q2	$25.5M	Hold	844,680	–	–	6.98%	4
2020 Q1	$25.2M	Buy	+844,680	New	+$22.7M	10.42%	4

Other funds holding ARQT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Omega Fund Management's ARQT Position: Q3 2022 in Review

Omega Fund Management sold out of Arcutis Biotherapeutics (ARQT) in Q3 2022, closing a stake of 623,836 shares — an estimated $13.3M sold.

Omega Fund Management first reported a position in ARQT in Q1 2020 and held it in 10 quarters. The position peaked at $25.5M in Q2 2020. 139 funds tracked by Wall St. Rank hold ARQT as of Q3 2022.

Omega Fund Management reported no remaining Arcutis Biotherapeutics position as of Q3 2022 after selling out during the quarter.
Omega Fund Management sold 623,836 Arcutis Biotherapeutics shares in Q3 2022, an estimated $13.3M.
Omega Fund Management first reported a position in Arcutis Biotherapeutics in Q1 2020 and held it in 10 quarters.
Omega Fund Management's Arcutis Biotherapeutics position peaked at $25.5M in Q2 2020.
139 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2022.

Based on Omega Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.